✉news BusinessLabor first seen 7 d ago, last 6 d ago, peak #25
Menarini and Georgiamune Sign $1.1 Billion Cancer Immunotherapy Deal
Original: Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy
Italy's Menarini Group has struck a licensing agreement worth up to $1.1 billion with US biotech Georgiamune to develop next-generation cancer immunotherapies. The deal gives Menarini rights to advance Georgiamune's pipeline, with payments tied to development and commercial milestones. The partnership highlights growing pharmaceutical interest in novel immunotherapy approaches as companies seek new oncology treatments beyond existing checkpoint inhibitors.
Why now: Major licensing deals in the competitive cancer immunotherapy field draw immediate industry and investor attention.
Rank over time, top of the chart is #1. 2 snapshots from 6 d ago to 6 d ago.
Evidence
- Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy · BioPharma APAC
API: https://socialmediatrends-api.osmike.com/v1/trends/3655434